NONHSAT076754 aids ultrasonography in predicting lymph node metastasis and promotes migration and invasion of papillary thyroid cancer cells

Oncotarget

Volumn 8, Issue 2, 2017, Pages 2293-2306

  Xia, Shujun ^a   Wang, Chuandong ^b   Ni, Xiaofeng ^a   Ni, Zhongxin ^a   Dong, Yijie ^a   Zhan, Weiwei ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Biomarker; Lymph node metastasis; NONHSAT076754; Papillary thyroid cancer; Ultrasonography

Indexed keywords

LONG NONCODING RNA NONHSAT076754; LONG UNTRANSLATED RNA; TUMOR MARKER; UNCLASSIFIED DRUG; LONG NONCODING RNA NONHSAT076754 , HUMAN;

ADULT; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CERVICAL LYMPH NODE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIGRATION INHIBITION; PREDICTION; THYROID PAPILLARY CARCINOMA; TUMOR INVASION; AGED; CELL MOTION; GENETICS; LYMPH NODE; MIDDLE AGED; NECK; PAPILLARY CARCINOMA; PATHOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; THYROID TUMOR; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA, LONG NONCODING; THYROID CANCER, PAPILLARY; THYROID NEOPLASMS; ULTRASONOGRAPHY;

EID: 85009758534     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13725     Document Type: Article

References (36)

1. Davies L and Welch HG. Current thyroid cancer trends in the United States. JAMA otolaryngology-head & neck surgery. 2014; 140:317-322
2. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. Cancer J Clin. 2014; 64:9-29
3. O'Grady TJ, Gates MA and Boscoe FP. Thyroid cancer incidence attributable to overdiagnosis in the United States 1981-2011. International journal of cancer. 2015; 137:2664-2673
4. Colonna M, Uhry Z, Guizard AV, Delafosse P, Schvartz C, Belot A, Grosclaude P and Network F. Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France. Cancer epidemiology. 2015; 39:511-518
5. DeGroot LJ, Kaplan EL, McCormick M and Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. The Journal of clinical endocrinology and metabolism. 1990; 71:414-424
6. Burman KD. Treatment of recurrent or persistent cervical node metastases in differentiated thyroid cancer: deceptively simple options. The Journal of clinical endocrinology and metabolism. 2012; 97:2623-2625
7. Suman P, Wang CH, Abadin SS, Moo-Young TA, Prinz RA and Winchester DJ. Risk factors for central lymph node metastasis in papillary thyroid carcinoma: A National Cancer Data Base (NCDB) study. Surgery. 2016; 159:31-39
8. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nature reviews Cancer. 2013; 13:184-199
9. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M and Robbins RJ. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001; 11:1169-1175
10. Patron V, Hitier M, Bedfert C, Le Clech G and Jegoux F. Occult lymph node metastases increase locoregional recurrence in differentiated thyroid carcinoma. The Annals of otology, rhinology, and laryngology. 2012; 121:283-290
11. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K and Miyauchi A. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World journal of surgery. 2006; 30:91-99
12. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K and Miyauchi A. Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World journal of surgery. 2005; 29:917-920
13. Struhl K. Transcriptional noise and the fidelity of initiation by RNA polymerase II. Nature structural & molecular biology. 2007; 14:103-105
14. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464:1071-1076
15. Sun J, Song Y, Chen X, Zhao J, Gao P, Huang X, Xu H and Wang Z. Novel long non-coding RNA RP11-119F7.4 as a potential biomarker for the development and progression of gastric cancer. Oncology letters. 2015; 10:115-120
16. Shappell SB. Clinical utility of prostate carcinoma molecular diagnostic tests. Reviews in urology. 2008; 10:44-69
17. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M and Zatloukal K. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007; 132:330-342
18. Orozco AF and Lewis DE. Flow cytometric analysis of circulating microparticles in plasma. Cytometry Part A. 2010; 77:502-514
19. Li-Korotky HS, Hebda PA, Lo CY and Dohar JE. Age-dependent differential expression of fibronectin variants in skin and airway mucosal wounds. Archives of otolaryngology-head & neck surgery. 2007; 133:919-924
20. Wang Y, Reheman A, Spring CM, Kalantari J, Marshall AH, Wolberg AS, Gross PL, Weitz JI, Rand ML, Mosher DF, Freedman J and Ni H. Plasma fibronectin supports hemostasis and regulates thrombosis. The Journal of clinical investigation. 2014; 124:4281-4293
21. Zhang C, Wu M, Zhang L, Shang LR, Fang JH and Zhuang SM. Fibrotic microenvironment promotes the metastatic seeding of tumor cells via activating the fibronectin 1/secreted phosphoprotein 1-integrin signaling. Oncotarget. 2016; doi: 10.18632/oncotarget.10157. [Epub ahead of print]
22. Kim E, Park JS, Son KR, Kim JH, Jeon SJ and Na DG. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid. 2008; 18:411-418
23. Chen XZ, Zhang WK, Yang K, Wang LL, Liu J, Wang L, Hu JK, Zhang B, Chen ZX, Chen JP, Zhou ZG and Mo XM. Correlation between serum CA724 and gastric cancer: multiple analyses based on Chinese population. Molecular biology reports. 2012; 39:9031-9039
24. Sun Z and Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World journal of surgical oncology. 2014; 12:397
25. Lee SE, Hwang TS, Choi YL, Han HS, Kim WS, Jang MH, Kim SK and Yang JH. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population. Thyroid. 2016; 26:901-910
26. Zhou X, Yin C, Dang Y, Ye F and Zhang G. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Scientific reports. 2015; 5:11516
27. Matouk IJ, Halle D, Raveh E, Gilon M, Sorin V and Hochberg A. The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision. Oncotarget. 2016; 7:3748-3765. doi: 10.18632/oncotarget.6387
28. Xu S, Wang P, You Z, Meng H, Mu G, Bai X, Zhang G, Zhang J and Pang D. The long non-coding RNA EPB41L4A-AS2 inhibits tumor proliferation and is associated with favorable prognoses in breast cancer and other solid tumors. Oncotarget. 2016; 7:20704-20717. doi: 10.18632/oncotarget.8007
29. Faouzi M, Hague F, Geerts D, Ay AS, Potier-Cartereau M, Ahidouch A and Ouadid-Ahidouch H. Functional cooperation between KCa3.1 and TRPC1 channels in human breast cancer: Role in cell proliferation and patient prognosis. Oncotarget. 2016; 7:36419-36435. doi: 10.18632/oncotarget.9261
30. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, Masse B, Piche L and Chypre C. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004; 64:311-315; discussion 315-316
31. Cocucci E, Racchetti G and Meldolesi J. Shedding microvesicles: artefacts no more. Trends in cell biology. 2009; 19:43-51
32. Aribas BK, Arda K, Ciledag N, Cetindag MF, Dogan K, Sahin G, Yologlu Z and Aktas E. Fine-needle aspiration biopsy of cervical lymph nodes: factors in predicting malignant diagnosis. Neoplasma. 2011; 58:51-57
33. Jiang B, Sun R, Fang S, Qin C, Pan X, Peng L, Li Y and Li G. Lnc-CC3 increases metastasis in cervical cancer by increasing Slug expression. Oncotarget. 2016; doi: 10.18632/oncotarget.9519
34. Sun TT, He J, Liang Q, Ren LL, Yan TT, Yu TC, Tang JY, Bao YJ, Hu Y, Lin Y, Sun D, Chen YX, Hong J, Chen H, Zou W and Fang JY. LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern. Cancer discovery. 2016; 6:784-801
35. Li W, Sun M, Zang C, Ma P, He J, Zhang M, Huang Z, Ding Y and Shu Y. Upregulated long non-coding RNA AGAP2-AS1 represses LATS2 and KLF2 expression through interacting with EZH2 and LSD1 in non-small-cell lung cancer cells. Cell death & disease. 2016; 7:e2225
36. Saiselet M, Floor S, Tarabichi M, Dom G, Hebrant A, van Staveren WC and Maenhaut C. Thyroid cancer cell lines: an overview. Frontiers in endocrinology. 2012; 3:133